Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Daniel Lee, Emily D. Clark, Inga M. Antonsdottir & Anton P. Porsteinsson. (2023) A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease. Expert Opinion on Pharmacotherapy 24:6, pages 691-703.
Read now
Read now
Cam Thanh Tran, Martin Bøg, Shuk-Li Collings, Michelle Johnson, Nawab Qizilbash, Stefan Lind, Ross A. Baker & Kristian Tore Jørgensen. (2022) Antipsychotic treatment patterns in Alzheimer’s disease patients with agitation: a cohort study using the UK clinical practice research datalink. Current Medical Research and Opinion 38:3, pages 409-416.
Read now
Read now
Jeremy Mills. (2022) Are Nurses Prescribing Lumateperone (Caplyta)?. Issues in Mental Health Nursing 43:1, pages 91-93.
Read now
Read now
Gulistan Bahat, Birkan Ilhan, Ilker Bay, Cihan Kilic, Pinar Kucukdagli, Meryem Merve Oren & Mehmet Akif Karan. (2020) Explicit versus implicit evaluation to detect inappropriate medication use in geriatric outpatients. The Aging Male 23:3, pages 179-184.
Read now
Read now
Natalia Niedziela, Maria Magdalena Nowak, Martyna Lis, Maria Blaszkowska, Rozalia Kośmider & Monika Adamczyk-Sowa. (2020) Atrial fibrillation as an important clinical condition of cognitive decline; diagnosis, comorbidities and severity of symptoms in patients with dementia. Neurological Research 42:5, pages 430-438.
Read now
Read now
Juan F. González, Andrés R. Alcántara, Antonio L. Doadrio & Jose María Sánchez-Montero. (2019) Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches. Expert Opinion on Drug Discovery 14:9, pages 879-891.
Read now
Read now
Articles from other publishers (47)
Parisa Karimi Tari, Chris G. Parsons, Graham L. Collingridge & Gerhard Rammes. (2024) Memantine: Updating a rare success story in pro-cognitive therapeutics. Neuropharmacology 244, pages 109737.
Crossref
Crossref
Shaikh Sheeran Naser, Dibyangshee Singh, Subham Preetam, Shristi Kishore, Lamha Kumar, Aditya Nandi, Faizan Zarreen Simnani, Anmol Choudhury, Adrija Sinha, Yogendra Kumar Mishra, Mrutyunjay Suar, Pritam Kumar Panda, Sumira Malik & Suresh K. Verma. (2023) Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression. Materials Today Bio 21, pages 100701.
Crossref
Crossref
Amanda Timler, Caroline Bulsara, Max Bulsara, Alistair Vickery, Angela Jacques & Jim Codde. (2023) Examining the use of cannabidiol and delta‐9‐tetrahydrocannabinol‐based medicine among individuals diagnosed with dementia living within residential aged care facilities: Results of a double‐blind randomised crossover trial. Australasian Journal on Ageing.
Crossref
Crossref
Christopher P Albertyn, Iskander Johar, Byron Creese, Allan Young, Ben Carter, Latha Velayudhan, Sagnik Bhattacharyya, Miguel Vasconcelos Da Silva, Kritika Samsi, Hassan Jafari, Ta-Wei Guu, Simrat Kaur, Pooja Kandangwa & Dag Aarsland. (2023) Sativex® for the treatment of Agitation & Aggression in Alzheimer’s Dementia in UK nursing homes (STAND): Protocol for a feasibility randomised controlled trial. Health Open Research 5, pages 18.
Crossref
Crossref
Peng Li & Michael Lämmerhofer. (2022)
Generation of
13
C-Labeled Inositol and Inositol Phosphates by Stable Isotope Labeling Cell Culture for Quantitative Metabolomics
. Analytical Chemistry 94:44, pages 15332-15340.
Crossref
Crossref
Dana M. Alhasan, Matthew C. Lohman, Jana A. Hirsch, Maggi C. Miller, Bo Cai & Chandra L. Jackson. (2022) Neighborhood characteristics and dementia symptomology among community-dwelling older adults with Alzheimer’s disease. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Ibtisam Mumtaz, Mir Owais Ayaz, Mohamad Sultan Khan, Umar Manzoor, Mohd Azhardin Ganayee, Aadil Qadir Bhat, Ghulam Hassan Dar, Badrah S. Alghamdi, Anwar M. Hashem, Mohd Jamal Dar, Gulam Md. Ashraf & Tariq Maqbool. (2022) Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer’s disease. Frontiers in Aging Neuroscience 14.
Crossref
Crossref
Mario F. Mendez. (2022) Managing the Behavioral and Psychological Symptoms of Dementia. Current Treatment Options in Neurology 24:5, pages 183-201.
Crossref
Crossref
Jordan R. Anderson & Michael Schrift. (2022) Medication Management of Neuropsychiatric Symptoms in Neurological Conditions: A Dimensional Transdiagnostic Approach. Seminars in Neurology 42:02, pages 225-236.
Crossref
Crossref
Sina Nawzad, Wiepke Cahn & Heshu Abdullah-Koolmees. (2022) The efficacy of antipsychotics in the treatment of physical aggressive behavior in patients with dementia in nursing homes. Therapeutic Advances in Psychopharmacology 12, pages 204512532210974.
Crossref
Crossref
Shankar Tumati, Nathan Herrmann, Giovanni Marotta, Abby Li & Krista L. Lanctôt. (2022) Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. Neurochemistry International 152, pages 105250.
Crossref
Crossref
Güler Duru Aşiret, Cemile Kütmeç Yılmaz & Kadriye Sayın Kasar. (2021)
Investigation of the effects of interventions made according to the
P
rogressively
L
owered
S
tress
T
hreshold
M
odel on the care outcomes of
A
lzheimer patients and their families: a randomized clinical trial
. Psychogeriatrics 21:5, pages 738-748.
Crossref
Crossref
Martin Steinberg. (2021) Update on Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. Current Geriatrics Reports 10:2, pages 51-57.
Crossref
Crossref
Anton P. Porsteinsson & Emily D. Clark. (2021) Point-of-care research in dementia – another arrow in our quiver?. International Psychogeriatrics 33:3, pages 199-200.
Crossref
Crossref
Vijayendra Waykar, Katherine Wourms, Ganapathy Bhat & Alison Farrow. (2021) Antipsychotic use in dementia – local quality improvement initiative. Progress in Neurology and Psychiatry 25:1, pages 26-30.
Crossref
Crossref
Petr D. Shabanov. (2020) Clinical pharmacology of pyrroxane (proroxane). Reviews on Clinical Pharmacology and Drug Therapy 18:4.
Crossref
Crossref
Petr D. Shabanov. (2020) Clinical pharmacology of pyrroxane (proroxane). Reviews on Clinical Pharmacology and Drug Therapy 18:4, pages 335-350.
Crossref
Crossref
Amanda Timler, Caroline Bulsara, Max Bulsara, Alistair Vickery, Jill Smith & Jim Codde. (2020) Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial. Trials 21:1.
Crossref
Crossref
Irina Monnard, Thierry Bénet, Rosemarie Jenni, Sean Austin, Irma Silva-Zolezzi & Jean-Philippe Godin. (2020) Plasma and urinary inositol isomer profiles measured by UHPLC-MS/MS reveal differences in scyllo-inositol levels between non-pregnant and pregnant women. Analytical and Bioanalytical Chemistry 412:28, pages 7871-7880.
Crossref
Crossref
Marianna Mazza, Giuseppe Marano, Gianandrea Traversi, Gabriele Sani & Luigi Janiri. (2020) Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders. CNS & Neurological Disorders - Drug Targets 19:4, pages 243-247.
Crossref
Crossref
Myrlene Sanon Aigbogun, Martin Cloutier, Marjolaine Gauthier-Loiselle, Annie Guerin, Martin Ladouceur, Ross A. Baker, Michael Grundman, Ruth A. Duffy, Ann Hartry, Keva Gwin & Howard Fillit. (2020) Real-World Treatment Patterns and Characteristics Among Patients with Agitation and Dementia in the United States: Findings from a Large, Observational, Retrospective Chart Review. Journal of Alzheimer's Disease 77:3, pages 1181-1194.
Crossref
Crossref
Lauren Stummer, Marija Markovic & Megan Maroney. (2020) Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer’s disease. Neurodegenerative Disease Management 10:4, pages 205-217.
Crossref
Crossref
Radoslaw Magierski, Tomasz Sobow, Emilia Schwertner & Dorota Religa. (2020) Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress. Frontiers in Pharmacology 11.
Crossref
Crossref
Shilpa Srinivasan, Rajesh R Tampi, Kripa Balaram & Arushi Kapoor. (2020) Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review. World Journal of Psychiatry 10:7, pages 162-174.
Crossref
Crossref
Vamsi Reddy, Dayton Grogan, Meenakshi Ahluwalia, Évila Lopes Salles, Pankaj Ahluwalia, Hesam Khodadadi, Katelyn Alverson, Andy Nguyen, Srikrishnan P. Raju, Pankaj Gaur, Molly Braun, Fernando L. Vale, Vincenzo Costigliola, Krishnan Dhandapani, Babak Baban & Kumar Vaibhav. (2020) Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. EPMA Journal 11:2, pages 217-250.
Crossref
Crossref
George T. Grossberg, Eva Kohegyi, Victor Mergel, Mette Krog Josiassen, Didier Meulien, Mary Hobart, Mary Slomkowski, Ross A. Baker, Robert D. McQuade & Jeffrey L. Cummings. (2020) Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. The American Journal of Geriatric Psychiatry 28:4, pages 383-400.
Crossref
Crossref
Filippo Caraci, Mario Santagati, Giuseppe Caruso, Dario Cannavò, Gian Marco Leggio, Salvatore Salomone & Filippo Drago. (2020) New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin. F1000Research 9, pages 686.
Crossref
Crossref
Horia Paunescu, Lorena Dima, Isabel Ghita, Laurenţiu Coman, Petru Iulian Ifteni, Ion Fulga & Oana Andreia Coman. (2020) A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. American Journal of Therapeutics 27:3, pages e249-e269.
Crossref
Crossref
Charles D. Ciccone. 2020. Guccione's Geriatric Physical Therapy. Guccione's Geriatric Physical Therapy
102
136
.
Valeria Calsolaro, Rachele Antognoli, Chukwuma Okoye & Fabio Monzani. (2019) The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease. Frontiers in Pharmacology 10.
Crossref
Crossref
Giulio E. Lancioni, Nirbhay N. Singh, Mark F. O’Reilly, Jeff Sigafoos, Fiora D’Amico, Barbara Turnone, Dominga Laporta, Antonella Scordamaglia & Katia Pinto. (2019) Smartphone-Based Interventions to Foster Simple Activity and Personal Satisfaction in People With Advanced Alzheimer’s Disease. American Journal of Alzheimer's Disease & Other Dementias® 34:7-8, pages 478-485.
Crossref
Crossref
Stephan Ehrhardt, Anton P. Porsteinsson, Cynthia A. Munro, Paul B. Rosenberg, Bruce G. Pollock, Davangere P. Devanand, Jacobo Mintzer, Tarek K. Rajji, Zahinoor Ismail, Lon S. Schneider, Sheriza N. Baksh, Lea T. Drye, Dimitri Avramopoulos, David M. Shade & Constantine G. Lyketsos. (2019) Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimer's & Dementia 15:11, pages 1427-1436.
Crossref
Crossref
Vimal M. Aga. (2019) When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram. The American Journal of Geriatric Psychiatry 27:10, pages 1099-1107.
Crossref
Crossref
Laurel J. Bessey & Art Walaszek. (2019) Management of Behavioral and Psychological Symptoms of Dementia. Current Psychiatry Reports 21:8.
Crossref
Crossref
Yaki Setty. (2019) eBrain: a Three Dimensional Simulation Tool to Study Drug Delivery in the Brain. Scientific Reports 9:1.
Crossref
Crossref
Rachel Halpern, Jerald Seare, Junliang Tong, Ann Hartry, Anthony Olaoye & Myrlene Sanon Aigbogun. (2018) Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia. International Journal of Geriatric Psychiatry 34:3, pages 420-431.
Crossref
Crossref
Martin Cloutier, Marjolaine Gauthier‐Loiselle, Patrick Gagnon‐Sanschagrin, Annie Guerin, Ann Hartry, Ross A. Baker, Ruth Duffy, Keva Gwin & Myrlene Sanon Aigbogun. (2019) Institutionalization risk and costs associated with agitation in Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 5:1, pages 851-861.
Crossref
Crossref
Rebecca Radue, Art Walaszek & Sanjay Asthana. 2019. Geriatric Neurology. Geriatric Neurology
437
454
.
Michelle Braun. 2019. Handbook on the Neuropsychology of Aging and Dementia. Handbook on the Neuropsychology of Aging and Dementia
355
364
.
Stephen M. Stahl. (2018) New hope for Alzheimer’s dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis. CNS Spectrums 23:5, pages 291-297.
Crossref
Crossref
Morgane Piton, Christophe Hirtz, Caroline Desmetz, Jacqueline Milhau, Anne Dominique Lajoix, Karim Bennys, Sylvain Lehmann & Audrey Gabelle. (2018) Alzheimer’s Disease: Advances in Drug Development. Journal of Alzheimer's Disease 65:1, pages 3-13.
Crossref
Crossref
Mairead M. Bartley, Laura Suarez, Reem M. A. Shafi, Joshua M. Baruth, Amanda J. M. Benarroch & Maria I. Lapid. (2018) Dementia Care at End of Life: Current Approaches. Current Psychiatry Reports 20:7.
Crossref
Crossref
Akihiko S. Kato & Jeffrey M. Witkin. (2018) Protein complexes as psychiatric and neurological drug targets. Biochemical Pharmacology 151, pages 263-281.
Crossref
Crossref
Nina Z. Xu, Margot Ernst, Marco Treven, Rok Cerne, Mark Wakulchik, Xia Li, Timothy M. Jones, Scott D. Gleason, Denise Morrow, Jeffrey M. Schkeryantz, Md. Toufiqur Rahman, Guanguan Li, Michael M. Poe, James M. Cook & Jeffrey M. Witkin. (2018) Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology 235:4, pages 1151-1161.
Crossref
Crossref
Angela C. Golas & Corinne E. Fischer. (2018) Antipsychotic Pharmacotherapy for Neuropsychiatric Symptoms of Dementia. Current Treatment Options in Psychiatry 5:1, pages 56-72.
Crossref
Crossref
Robert Wilhelm, Björn Ahl & Ion-George Anghelescu. (2017) Dextrometorphan-Paroxetine, But Not Dronabinol, Effective for Treatment-Resistant Aggression and Agitation in an Elderly Patient With Lewy Body Dementia. Journal of Clinical Psychopharmacology 37:6, pages 745-747.
Crossref
Crossref
Johannes Rosenboom. (2017) Medikamentöse Alternativen zu Antipsychotika bei Verhaltensstörungen. DNP - Der Neurologe & Psychiater 18:9-10, pages 53-64.
Crossref
Crossref